Drug recalled sits at the center of this dementia and brain health question.
Several major drugs have been pulled from shelves in early 2026 after the FDA discovered contamination ranging from potential carcinogens to rodent feces. The most alarming recall involves Teva Pharmaceuticals’ metoprolol succinate, a widely prescribed blood pressure medication, which the FDA upgraded to a Class II recall in March 2026 after finding potential carcinogenic contamination that may increase the risk of liver, stomach, and lung tumors with prolonged exposure. Over 112,000 bottles have been recalled nationwide across multiple strengths, from 25 mg to 200 mg tablets. But metoprolol is far from the only medication affected.
A massive recall tied to a Minneapolis warehouse run by Gold Star Distribution swept up nearly 2,000 over-the-counter products — including household names like Advil, Tylenol, NyQuil, and Tums — after FDA investigators found rodent feces, rodent urine, and bird droppings contaminating the storage facility. Meanwhile, Novo Nordisk voluntarily recalled four lots of its blockbuster weight-loss drug Wegovy after a hair was discovered inside a prefilled syringe. For older adults, especially those managing chronic conditions like hypertension, high cholesterol, or cognitive decline, these recalls carry real urgency. This article covers the full list of recalled drugs in early 2026, explains what the FDA classifications actually mean, and walks through the specific steps you should take if any of these medications are sitting in your medicine cabinet right now.
Table of Contents
- Which Drugs Were Recalled After FDA Contamination Discoveries in 2026?
- What Do FDA Recall Classifications Mean for Your Safety?
- Why Contaminated Drugs Pose Heightened Risks for Older Adults and Dementia Patients
- How to Check If Your Medication Is Affected and What to Do Next
- The Dissolution Problem — When Pills Do Not Work as Designed
- Rodent Contamination and the Supply Chain Vulnerability You Cannot See
- What to Expect From FDA Enforcement Going Forward
- Conclusion
- Frequently Asked Questions
Which Drugs Were Recalled After FDA Contamination Discoveries in 2026?
The fda has flagged at least seven significant drug recalls since late 2025, each involving a different type of contamination or manufacturing failure. The Teva metoprolol succinate recall is the most serious for people managing cardiovascular health. Affected lot numbers include 0715J251, 0716J251, and 0717J251 for the 25 mg strength; 0486G251, 0487G251, and 0488G251 for the 50 mg tablets; 0718J251, 0729J251, and 0730J251 for 100 mg; and 0686H251 and 0687H251 for the 200 mg dose, among others. The contamination involves failed dissolution testing alongside potential carcinogenic impurities — a combination that prompted the FDA to elevate the recall’s urgency from Class III to Class II. The Gold Star Distribution recall dwarfs the others in sheer scope. Forty-four pages of recalled products cover items distributed to more than 50 stores across Minnesota, with additional stores in Fargo, North Dakota, and Indianapolis, Indiana.
The FDA investigation revealed that these over-the-counter medications — Bayer Aspirin, Claritin, Pepto Bismol, Pepcid Complete, Halls Cough Drops, and many more — were stored in a warehouse contaminated with animal waste. The primary concern is salmonella, which can be fatal in vulnerable populations including infants, the elderly, pregnant individuals, and anyone with a compromised immune system. As of the recall date, no illnesses had been reported. Rising Pharmaceuticals also recalled 1,200 bottles of temozolomide capsules (5 mg strength) in March 2026 after the cancer drug failed impurities and degradation specifications during nine-month stability testing. And AvKare recalled its amantadine hydrochloride capsules (100 mg, liquid filled, 50-capsule unit dose packs) after the pills failed dissolution specifications — meaning they may not dissolve properly in the body, rendering the medication ineffective. For anyone taking amantadine to manage Parkinson’s symptoms or drug-induced movement disorders, that loss of effectiveness is not a minor inconvenience.
What Do FDA Recall Classifications Mean for Your Safety?
The FDA uses three classification levels, and understanding the difference matters when deciding how urgently to act. A Class I recall is the most severe — it means there is a reasonable probability that the product will cause serious adverse health consequences or death. Class II, which applies to the metoprolol and Wegovy recalls, indicates that the product may cause temporary or medically reversible adverse health effects, though the probability of serious harm is remote. Class III is the least urgent, covering products unlikely to cause adverse health effects but that violate FDA standards. However, a Class II designation does not mean you can wait around. The metoprolol recall was initially classified as Class III before being upgraded, which illustrates that the FDA’s understanding of risk can evolve as more data comes in. The potential for carcinogenic contamination — with links to liver, stomach, and lung tumors — is not something that becomes dangerous only after a single dose.
The concern is cumulative exposure over time, which is exactly the pattern for someone taking a daily blood pressure medication. If you have been on a recalled lot of metoprolol for several months, the conversation with your doctor should happen soon, not eventually. The Wegovy recall is worth putting in context. Novo Nordisk states that the affected lots — four batches of prefilled pens in 0.5 mg and 1 mg dosages — were never actually sent to patients or retailers. The company caught the hair contamination during routine inspection. No adverse effects have been reported. While a foreign particle inside an injectable pen is genuinely concerning from a sterility standpoint, this particular recall appears to have been contained before reaching consumers.
Why Contaminated Drugs Pose Heightened Risks for Older Adults and Dementia Patients
Older adults face disproportionate risk from contaminated medications for several overlapping reasons. Their immune systems are typically weaker, making infections like salmonella more dangerous. They are more likely to be taking multiple medications, increasing the chances that at least one of those drugs falls under a recall. And they are less likely to hear about recalls through the channels that younger adults rely on, such as social media or news apps. For people living with dementia, the situation compounds further.
A person with moderate cognitive impairment may not be able to check their own medication lot numbers, may not remember which pharmacy filled their prescription, and may not be equipped to advocate for themselves with a healthcare provider. This is where caregivers become the frontline. If you are caring for someone with dementia who takes metoprolol for blood pressure, rosuvastatin for cholesterol (AvKare recalled thousands of bottles of rosuvastatin tablets in 2026 due to manufacturing defects), or amantadine for movement symptoms, you need to physically check those bottles yourself. The Gold Star Distribution recall is particularly relevant here because it involves everyday medications that many older adults take without a second thought — antacids like Tums, allergy pills like Claritin, and pain relievers like Advil and Tylenol. These are products people buy off the shelf and assume are safe. If you purchased any of these products from stores in Minnesota, Fargo, or Indianapolis in late 2025 or early 2026, check the specific lot information against the FDA’s 44-page list regardless of whether anyone in your household has shown symptoms.
How to Check If Your Medication Is Affected and What to Do Next
Start with the physical bottle or packaging. Every prescription and OTC medication has a lot number printed on the label or stamped onto the packaging. Compare that number against the FDA’s official recall list, which is updated continuously at the FDA Drug Recalls page. For the metoprolol recall specifically, you are looking at extended-release tablets across all four strengths (25 mg, 50 mg, 100 mg, and 200 mg) manufactured by Teva Pharmaceuticals. If your lot number matches, do not simply stop taking the medication — abruptly discontinuing a blood pressure drug can cause rebound hypertension, which in older adults can trigger a stroke or cardiac event. Instead, contact your prescribing physician or pharmacist and ask for a replacement from an unaffected lot or an alternative medication. Most pharmacies have systems to flag recalled products and will proactively reach out to affected patients, but these systems are imperfect.
Do not assume you will be contacted. For the OTC products in the Gold Star recall, the tradeoff is simpler: discard the product and replace it. The salmonella risk from contaminated storage conditions is not something you can inspect for visually or by smell. There is a meaningful difference between how you handle a recall for contamination versus one for subpotency. Zydus Pharmaceuticals recalled approximately 22,896 bottles of icosapent ethyl capsules in 2026 because the drug was subpotent — it did not contain enough active ingredient. A subpotent medication will not poison you, but it also will not work. If your triglyceride or cardiovascular medication is not doing its job because the pills are underdosed, the risk is that your underlying condition goes untreated. For someone already at elevated risk for vascular dementia or stroke, that gap in treatment matters.
The Dissolution Problem — When Pills Do Not Work as Designed
Two of the 2026 recalls — metoprolol and amantadine — involve dissolution failures, and this is a problem that deserves more attention than it typically receives. Dissolution testing measures how effectively a tablet or capsule breaks down and releases its active ingredient in conditions that simulate the human digestive system. When a drug fails dissolution specifications, it means the medication may pass through your body without ever delivering its intended dose, or it may release the active ingredient too quickly or unevenly. For extended-release formulations like metoprolol succinate, dissolution is especially critical. The entire design of an extended-release tablet depends on a controlled, gradual release of medication over many hours. If that mechanism is compromised, you could get a spike of the drug followed by nothing, or inadequate levels throughout the day.
For a blood pressure medication, this means your blood pressure may not be controlled during the periods when the drug is underperforming — typically overnight and in the early morning, which is precisely when cardiovascular events are most common in older adults. The amantadine recall highlights a related but distinct concern. Amantadine is used in some cases to manage fatigue, movement disorders, and certain off-label cognitive applications. If the liquid-filled capsules are not dissolving properly, you are essentially taking a placebo. There is no way for a patient to tell the difference between a working pill and one that is passing through intact. If you or someone you are caring for has noticed a worsening of symptoms despite medication adherence, a dissolution-related manufacturing defect is one possible explanation worth raising with a pharmacist.
Rodent Contamination and the Supply Chain Vulnerability You Cannot See
The Gold Star Distribution recall is disturbing not because of what was in the drugs themselves but because of what was in the facility where they were stored. The FDA found rodent feces, rodent urine, and bird droppings in the Minneapolis warehouse — conditions that create a risk of salmonella contamination across every product housed there. This is a supply chain problem, not a manufacturing problem, and that distinction matters. The drugs were presumably manufactured under proper conditions, then degraded by a distributor’s warehouse practices.
This is a blind spot for most consumers. You can research a drug manufacturer’s safety record, read about FDA warning letters sent to production facilities overseas, and still end up with a contaminated product because the last mile of the supply chain failed. Nearly 2,000 products were compromised in a single warehouse. For caregivers managing complex medication regimens for someone with dementia, this kind of recall is a reminder to buy from well-established pharmacy chains with documented storage and handling protocols whenever possible.
What to Expect From FDA Enforcement Going Forward
The FDA has been under increasing pressure to improve its recall communication and enforcement speed. The metoprolol situation — where the recall was initially classified at the lowest urgency level and only later upgraded to Class II — raises questions about whether the classification system moves quickly enough to protect patients who are taking these drugs daily. A recall that sits at Class III for weeks while patients continue to take potentially carcinogenic pills is a systemic problem, not just a labeling issue. Looking ahead, the volume and variety of recalls in early 2026 suggest that manufacturing quality and supply chain oversight remain persistent vulnerabilities.
From cancer-linked impurities in blood pressure drugs to rodent waste in OTC storage warehouses to subpotent cardiovascular medications, the failure modes are diverse. For older adults and their caregivers, the practical takeaway is that vigilance cannot be outsourced entirely to the system. Checking the FDA’s recall page periodically, maintaining an updated medication list with lot numbers, and building a relationship with a pharmacist who will flag issues proactively — these are not optional precautions. They are baseline self-defense.
Conclusion
The early months of 2026 have brought an unsettling wave of FDA drug recalls, with contamination concerns ranging from carcinogenic impurities in Teva’s metoprolol succinate to rodent waste in a distribution warehouse that handled Advil, Tylenol, and dozens of other household medications. Additional recalls have hit cancer drugs, cholesterol medications, weight-loss injectables, and pills used to manage movement disorders. For older adults managing chronic health conditions — and for caregivers supporting someone with dementia — these recalls are not abstract regulatory events. They are immediate, practical problems that require checking medicine cabinets, calling pharmacists, and coordinating with doctors.
Do not stop any prescribed medication without medical guidance, but do not delay action either. Check the FDA’s official drug recall page for the most current information, verify lot numbers on every bottle in your home, and talk to your pharmacist about sourcing replacements from unaffected manufacturers. If you are a caregiver, add a recurring medication audit to your routine. The system catches most problems eventually, but eventually is not fast enough when someone you love is taking a potentially contaminated pill every morning.
Frequently Asked Questions
How do I find the lot number on my medication bottle?
The lot number is typically printed on the label of the prescription bottle or stamped on the outer packaging of OTC products. It may be labeled as “Lot #,” “LOT,” or “Batch.” If you cannot locate it, your pharmacist can look it up using your prescription records.
Should I stop taking my blood pressure medication if it is on the recall list?
Do not stop taking metoprolol or any blood pressure medication abruptly without consulting your doctor. Suddenly discontinuing blood pressure drugs can cause dangerous spikes in blood pressure. Contact your physician or pharmacist to arrange a replacement from an unaffected lot or an alternative medication.
Were any illnesses reported from the Gold Star Distribution warehouse contamination?
As of the recall announcement, no illnesses had been reported in connection with the Gold Star Distribution recall. However, the FDA warned that salmonella contamination poses serious risks to infants, the elderly, pregnant individuals, and immunocompromised people, and urged consumers to discard affected products.
Is the Wegovy recall something patients need to worry about?
Novo Nordisk has stated that the four affected lots of Wegovy prefilled pens were never distributed to patients or retailers. The recall was triggered by a hair found inside a prefilled syringe during routine inspection. No adverse effects have been reported, and the risk to patients appears minimal given the products did not reach the market.
How often should I check for FDA drug recalls?
There is no set schedule, but checking the FDA Drug Recalls page monthly is a reasonable habit, especially if you or someone in your care takes multiple medications. You can also sign up for FDA safety alerts by email, and many pharmacy chains have systems that automatically notify patients about recalled products.
Does a failed dissolution test mean my medication is dangerous?
Not necessarily dangerous in the way contamination is, but potentially ineffective. A pill that does not dissolve properly may not deliver its active ingredient as intended, meaning your condition may go undertreated. For medications managing blood pressure, cholesterol, or neurological symptoms, undertreated conditions carry their own serious risks.
You Might Also Like
- The Injectable Migraine Drug Working in 30 Minutes Flat
- The Hepatitis B Drug That Controls the Virus but Never Cures It
- The Drug Changing Lives of Spinal Muscular Atrophy Patients
For more, see NIH MedlinePlus — cognitive testing.
